Open AccessIntraoperative Mass Spectrometry Platform for IDH Mutation Status Prediction, Glioma Diagnosis, and Estimation of Tumor Cell Infiltration
Author(s) -
Hannah Marie Brown,
Clint M. Alfaro,
Valentina Pirro,
Mahua Dey,
Eyas M. Hattab,
Aaron Cohen-Gadol,
R. Graham Cooks
Publication year - 2021
Publication title -
the journal of applied laboratory medicine
Language(s) - English
Resource type - Journals
eISSN - 2576-9456
pISSN - 2475-7241
DOI - 10.1093/jalm/jfaa233
Subject(s) - isocitrate dehydrogenase , medicine , glioma , univariate analysis , oncology , pathology , radiology , multivariate analysis , cancer research , biology , biochemistry , enzyme
Surgical tumor resection is the primary treatment option for diffuse glioma, the most common malignant brain cancer. The intraoperative diagnosis of gliomas from tumor core samples can be improved by use of molecular diagnostics. Further, residual tumor at surgical margins is a primary cause of tumor recurrence and malignant progression. This study evaluates a desorption electrospray ionization mass spectrometry (DESI-MS) system for intraoperative isocitrate dehydrogenase (IDH) mutation assessment, estimation of tumor cell infiltration as tumor cell percentage (TCP), and disease status. This information could be used to enhance the extent of safe resection and so potentially improve patient outcomes.